Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/171944
Title: | Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2) |
Author: | Nemejcova, Kristyna Kocian, Roman Kohler, Christhardt Jarkovsky, Jiri Klat, Jaroslav Berjon, Alberto Pilka, Radovan Sehnal, Borek Gil Ibáñez, Blanca Lupo, Ezequiel Petiz, Almerinda Arencibia Sánchez, Octavio Kascak, Peter Martinelli, Fabio Buda, Alessandro Presl, Jiri Barahona, Marc van Lonkhuijzen, Luc Szatkowski, Wiktor Minar, Lubos Pakiz, Maja Havelka, Pavel Zorrero, Cristina Misiek, Marcin Snyman, Leon Cornelius Wydra, Dariusz Vergote, Ignace Vinnytska, Alla Redecha, Mikulas Michal, Martin Tingulstad, Solveig Kipp, Barbara Szewczyk, Grzegorz Toth, Robert Santiago Garcia, Francisco Javier de Coronado Martín, Pluvio Jesús Poka, Robert Tamussino, Karl Luyckx, Mathieu Fastrez, Maxime Staringer, Juan Carlos Germanova, Anna Plaikner, Andrea Bajsova, Sylvia Dundr, Pavel Mallmann Gottschalk, Nina Cibula, David |
Keywords: | Càncer de coll uterí Metàstasi Nodes limfàtics Cervix cancer Metastasis Lymph nodes |
Issue Date: | 1-May-2020 |
Publisher: | MDPI |
Abstract: | The quality of pathological assessment is crucial for the safety of patients with cervical cancer if pelvic lymph node dissection is to be replaced by sentinel lymph node (SLN) biopsy. Central pathology review of SLN pathological ultrastaging was conducted in the prospective SENTIX/European Network of Gynaecological Oncological Trial (ENGOT)-CX2 study. All specimens from at least two patients per site were submitted for the central review. For cases with major or critical deviations, the sites were requested to submit all samples from all additional patients for second-round assessment. From the group of 300 patients, samples from 83 cases from 37 sites were reviewed in the first round. Minor, major, critical, and no deviations were identified in 28%, 19%, 14%, and 39% of cases, respectively. Samples from 26 patients were submitted for the second-round review, with only two major deviations found. In conclusion, a high rate of major or critical deviations was identified in the first round of the central pathology review (28% of samples). This reflects a substantial heterogeneity in current practice, despite trial protocol requirements. The importance of the central review conducted prospectively at the early phase of the trial is demonstrated by a substantial improvement of SLN ultrastaging quality in the second-round review. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/cancers12051115 |
It is part of: | Cancers, 2020-05-01, vol. 12, num. 5 |
URI: | http://hdl.handle.net/2445/171944 |
Related resource: | https://doi.org/10.3390/cancers12051115 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
NemejcovaK.pdf | 810.88 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License